Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Cellectis S.A.

CMVLFPNK
Healthcare
Biotechnology
$4.50
$0.10(2.27%)
U.S. Market opens in 9h 43m

Cellectis S.A. Fundamental Analysis

Cellectis S.A. (CMVLF) shows moderate financial fundamentals with a PE ratio of -12.77, profit margin of -46.97%, and ROE of -31.79%. The company generates $0.1B in annual revenue with strong year-over-year growth of 53.97%.

Key Strengths

Cash Position11.57%
PEG Ratio-0.32

Areas of Concern

ROE-31.79%
Operating Margin-35.08%
We analyze CMVLF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -23.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-23.8/100

We analyze CMVLF's fundamental strength across five key dimensions:

Efficiency Score

Weak

CMVLF struggles to generate sufficient returns from assets.

ROA > 10%
-10.31%

Valuation Score

Excellent

CMVLF trades at attractive valuation levels.

PE < 25
-12.77
PEG Ratio < 2
-0.32

Growth Score

Excellent

CMVLF delivers strong and consistent growth momentum.

Revenue Growth > 5%
53.97%
EPS Growth > 10%
80.29%

Financial Health Score

Excellent

CMVLF maintains a strong and stable balance sheet.

Debt/Equity < 1
0.37
Current Ratio > 1
1.49

Profitability Score

Weak

CMVLF struggles to sustain strong margins.

ROE > 15%
-3178.95%
Net Margin ≥ 15%
-46.97%
Positive Free Cash Flow
No

Key Financial Metrics

Is CMVLF Expensive or Cheap?

P/E Ratio

CMVLF trades at -12.77 times earnings. This suggests potential undervaluation.

-12.77

PEG Ratio

When adjusting for growth, CMVLF's PEG of -0.32 indicates potential undervaluation.

-0.32

Price to Book

The market values Cellectis S.A. at 4.49 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

4.49

EV/EBITDA

Enterprise value stands at -42.94 times EBITDA. This is generally considered low.

-42.94

How Well Does CMVLF Make Money?

Net Profit Margin

For every $100 in sales, Cellectis S.A. keeps $-46.97 as profit after all expenses.

-46.97%

Operating Margin

Core operations generate -35.08 in profit for every $100 in revenue, before interest and taxes.

-35.08%

ROE

Management delivers $-31.79 in profit for every $100 of shareholder equity.

-31.79%

ROA

Cellectis S.A. generates $-10.31 in profit for every $100 in assets, demonstrating efficient asset deployment.

-10.31%

Following the Money - Real Cash Generation

Operating Cash Flow

Cellectis S.A. generates limited operating cash flow of $-20.97M, signaling weaker underlying cash strength.

$-20.97M

Free Cash Flow

Cellectis S.A. generates weak or negative free cash flow of $-23.58M, restricting financial flexibility.

$-23.58M

FCF Per Share

Each share generates $-0.33 in free cash annually.

$-0.33

FCF Yield

CMVLF converts -10.05% of its market value into free cash.

-10.05%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-12.77

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.32

vs 25 benchmark

P/B Ratio

Price to book value ratio

4.49

vs 25 benchmark

P/S Ratio

Price to sales ratio

4.32

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.37

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.49

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.32

vs 25 benchmark

ROA

Return on assets percentage

-0.10

vs 25 benchmark

ROCE

Return on capital employed

-0.14

vs 25 benchmark

How CMVLF Stacks Against Its Sector Peers

MetricCMVLF ValueSector AveragePerformance
P/E Ratio-12.7729.45 Better (Cheaper)
ROE-31.79%779.00% Weak
Net Margin-46.97%-24936.00% (disorted) Weak
Debt/Equity0.370.26 Weak (High Leverage)
Current Ratio1.494.65 Neutral
ROA-10.31%-19344.00% (disorted) Weak

CMVLF outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Cellectis S.A.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

28.82%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

80.89%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

115.68%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ